Research

Hormonal

Semaglutide treatment in Type 2 Diabetes Mellitus patients significantly reduces HbA1c, fasting plasma glucose, and body weight while improving renal markers (ACR) over a 12-month period.

If you have Type 2 Diabetes, Semaglutide is a highly effective treatment for lowering blood sugar (HbA1c) and losing weight. It is taken as a once-weekly injection, starting at a low dose to minimize side effects like nausea. This treatment also helps protect kidney function by reducing albumin in the urine. Consistency is key, as benefits are maintained over time.

ModerateSupportsMEDIUM confidence
This real-world evidence shows the efficacy of semaglutide in achieving treatment goals in patients with T2DM... reduction of glycated hemoglobin levels (MD −2.74 CI −1.95 to −3.52 in 6 months), fasting plasma glucose levels, body weight (MD −7.11 CI −5.97 to −8.24), and the albumin-to-creatinine ratio.
Carlos Mario Balcázar Valencia et al. · Diabetes Metabolic Syndrome and Obesity · 2024

Why this rating

Observational retrospective cohort study with a small sample size (n=49) and potential biases, though results align with larger RCTs.

Source

Semaglutide Effects on Metabolic Outcomes in Diabetes Mellitus Patients — Real World Study

Carlos Mario Balcázar Valencia et al. · Diabetes Metabolic Syndrome and Obesity · 2024

DOI 10.2147/dmso.s443115

cohort · n=49Cited 2×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →